milrinone has been researched along with caffeine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 3 (18.75) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Copelas, L; Feldman, MD; Grossman, W; Gwathmey, JK; Morgan, JP; Phillips, P; Schoen, FJ; Warren, SE | 1 |
| Allen, PD; Alousi, AA; Grant, AM; Pagani, ED | 1 |
| Gwathmey, JK; Morgan, JP | 2 |
| Delgado, C; Sesin, J; Tamargo, J; Tejerina, T | 1 |
| Bjerkås, H; Helle, KB; Lønning, K | 1 |
| Aardal, S; Helle, KB; Lillestłl, IK | 1 |
| Bajnok, A; Orbán, C; Sava, F; Toldi, G; Vásárhelyi, Z | 1 |
1 review(s) available for milrinone and caffeine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for milrinone and caffeine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure.
Topics: 1-Methyl-3-isobutylxanthine; Caffeine; Calcium; Cardiotonic Agents; Colforsin; Cyclic AMP; Heart Failure; Humans; Isoproterenol; Milrinone; Myocardial Contraction; Myocardium; Pyridones; Stimulation, Chemical; Strophanthidin | 1987 |
Effects of milrinone on Ca++-sensitivity of myofibrillar Mg-adenosine triphosphatase isolated from normal human and canine hearts.
Topics: Animals; Ca(2+) Mg(2+)-ATPase; Caffeine; Calcium; Dogs; Drug Interactions; Heart; Humans; Milrinone; Myocardium; Pyridones | 1988 |
The effects of milrinone and piroximone on intracellular calcium handling in working myocardium from the ferret.
Topics: Aequorin; Animals; Caffeine; Calcium; Cardiotonic Agents; Cyclic AMP; Ferrets; Imidazoles; In Vitro Techniques; Male; Milrinone; Myocardial Contraction; Myocardium; Pyridones; Time Factors | 1985 |
Effect of milrinone on contractility and 45Ca movements in the isolated rabbit aorta.
Topics: Animals; Aorta, Thoracic; Caffeine; Calcium; Calcium Radioisotopes; Cardiotonic Agents; Female; In Vitro Techniques; Male; Milrinone; Norepinephrine; Potassium; Pyridones; Rabbits; Vasoconstriction; Vasodilator Agents | 1988 |
Sarcoplasmic reticulum calcium mobilization in right ventricular pressure-overload hypertrophy in the ferret: relationships to diastolic dysfunction and a negative treppe.
Topics: Action Potentials; Animals; Caffeine; Calcium; Diastole; Electric Stimulation; Ferrets; Hypertrophy, Right Ventricular; Isoproterenol; Kinetics; Male; Membrane Potentials; Milrinone; Myocardial Contraction; Potassium; Pressure; Pyridones; Sarcoplasmic Reticulum | 1993 |
The adrenomedullary venous vasculature as a target for endothelins: comparison of the porcine and bovine central adrenomedullary veins.
Topics: Acetylcholine; Adenylyl Cyclases; Adrenal Medulla; Animals; Caffeine; Cattle; Colforsin; Cyclic AMP; Endothelin-1; Milrinone; Muscle, Smooth, Vascular; Neuropeptide Y; Potassium; Propranolol; Receptor, Endothelin A; Receptors, Endothelin; Second Messenger Systems; Species Specificity; Swine; Vasoactive Intestinal Peptide; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents; Veins | 1998 |
Relaxing effects of cyclic GMP and cyclic AMP-enhancing agents on the long-lasting contraction to endothelin-1 in the porcine coronary artery.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Animals; Atrial Natriuretic Factor; Caffeine; Calcium Channel Blockers; Calcium Channels; Calcium Channels, L-Type; Colforsin; Coronary Vessels; Cyclic AMP; Cyclic GMP; Dose-Response Relationship, Drug; Endothelin-1; In Vitro Techniques; Isradipine; Milrinone; Muscle, Smooth, Vascular; Papaverine; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Purinones; Pyrrolidinones; Rolipram; Swine; Vasoactive Intestinal Peptide; Vasoconstriction; Vasodilation; Verapamil; Vinca Alkaloids | 1998 |
Effects of caffeine and phosphodiesterase inhibitors on activation of neonatal T lymphocytes.
Topics: Adenosine A2 Receptor Antagonists; Adult; Aging; Caffeine; Calcium Signaling; Cells, Cultured; Cyclic AMP; Cytokines; Female; Humans; Infant, Newborn; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Milrinone; Phosphodiesterase Inhibitors; Reactive Oxygen Species; Sildenafil Citrate; T-Lymphocytes; Triazines; Triazoles | 2018 |